 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
56 News |  |
- ||| nanocrystalline form of fluticasone (AC-155) / Nicox
Enrollment change: Mississippi: Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis (clinicaltrials.gov) - Dec 14, 2022
P2b, N=224, Completed, Sponsor: Nicox Ophthalmics, Inc.
N=320 --> 224
- nanocrystalline form of fluticasone (AC-155) / Nicox, Vyzulta (latanoprostene bunod) / Bausch Health, Nicox, nitric oxide (NO)‑donating bimatoprost analog (NCX 470) / Nicox
Nicox (Theater 3) - Jun 4, 2022 - Abstract #BIO2022BIO_203;
Our ophthalmic pipeline includes two programs in clinical development, NCX 470 targeting glaucoma and NCX 4251 targeting dry eye disease. We also have two products which are commercialized in the U.S., VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively.
- nanocrystalline form of fluticasone (AC-155) / Nicox
Eyelid Application of NCX 4251 for Treatment of Signs and Symptoms of Dry Eye Disease (A0267) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3345;
NCX 4251 has the potential to provide a safe and efficacious short-term treatment for DED. The encouraging findings from this post hoc analysis must be confirmed in larger prospective clinical trials.
- |||| nanocrystalline form of fluticasone (AC-155) / Nicox
Trial completion, Trial completion date, Trial primary completion date: Mississippi: Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis (clinicaltrials.gov) - Jul 1, 2021
P2b, N=320, Completed, Sponsor: Nicox Ophthalmics, Inc.
The encouraging findings from this post hoc analysis must be confirmed in larger prospective clinical trials. Recruiting --> Completed | Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Jun 2021
- |||||| nanocrystalline form of fluticasone (AC-155) / Nicox
New P2b trial: Mississippi: Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis (clinicaltrials.gov) - Dec 19, 2020
P2b, N=300, Recruiting, Sponsor: Nicox Ophthalmics, Inc.
- nanocrystalline form of fluticasone (AC-155) / Nicox, PVS-RIPO / Istari Oncology
[VIRTUAL] Oncolytic poliovirus as a probe for mechanisms of immune resistance in glioblastoma () - Oct 24, 2020 - Abstract #SNO2020SNO_829;
This model is valuable in studying the mechanisms of intrinsic resistance and the timeline of resistance to develop in order to obtain more durable immunotherapy responses in glioblastoma. Future steps are to track inflammation induced by viral infection by RNAseq, and to find potential therapeutic interventions (including blocking PD1:PD-L1 axis) to mitigate therapy resistance in this preclinical model.
- nanocrystalline form of fluticasone (AC-155) / Nicox
[VIRTUAL] Prospective Study of NCX 4251 (fluticasone propionate nanocrystals ophthalmic suspension, 0.1%) for Treatment of Blepharitis (VM) - May 23, 2020 - Abstract #ASCRSASOA2020ASCRS-ASOA_2134;
Conclusion NCX 4251 has the potential to provide an effective and rapid relief of signs and symptoms of blepharitis and dry eye. The well-known efficacy of fluticasone propionate in treating inflammation, along with the safety profile of the novel formulation and its delivery method represent an important advance in the treatment of this debilitating disease.
- || nanocrystalline form of fluticasone (AC-155) / Nicox
Trial completion: Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis (clinicaltrials.gov) - Jan 13, 2020
P2, N=44, Completed, Sponsor: Nicox Ophthalmics, Inc.
The well-known efficacy of fluticasone propionate in treating inflammation, along with the safety profile of the novel formulation and its delivery method represent an important advance in the treatment of this debilitating disease. Recruiting --> Completed
- || nanocrystalline form of fluticasone (AC-155) / Nicox
New P2 trial: Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis (clinicaltrials.gov) - Apr 23, 2019
P2, N=40, Recruiting, Sponsor: Nicox Ophthalmics, Inc.